Portal de investigación
ESTUDIO MULTICENTRICO EN ABIERTO PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD LOCAL, LA COMODIDAD POSOLOGICA Y LA EFICACIA DE UNA FORMULACION AUTOADMINISTRADA POR VIA SUBCUTANEA DE ICATIBANT EN EL TRATAMIENTO DE LOS ATAQUES AGUDOS DE ANGIOEDEMA HEREDITARIO
Datos básicos
- Código:
- JE049-3101
- Protocolo:
- JE049-3101
- EUDRACT:
- 2008-000071-25
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
JERINI AG
Resultados del Ensayo Clínico
[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review.
Mansilla-Polo M, Gimeno E, Morgado-Carrasco D
Article. 10.1016/j.ad.2024.01.009. 2024
Actualización de las recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (COVID-19) en pacientes con trasplante renal.
López V; (...); Hernández D
Article. 10.1016/j.nefro.2022.11.001. 2023
An ultra-sensitive homologous chemiluminescence immunoassay to tackle penicillin allergy.
Quintero-Campos P; (...); Morais S
Article. 10.1016/j.aca.2022.339940. 2022
Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers
Perales-Chorda C; (...); de Rojas, DHF
Article. 10.1111/cea.13991. 2021
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Ribera JM; (...); Sancho JM
Article. 10.3324/haematol.2023.283342. 2024
Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain.
Guilarte M; (...); IOS Study Group
Article. 10.1186/s13223-021-00641-3. 2021
Live donor kidney transplantation. Situation analysis and roadmap.
de la Oliva Valentín M; (...); Domínguez-Gil B
Article. 10.1016/j.nefroe.2022.02.002. 2022
Multiplexed analytical approaches to beta-lactam allergy in vitro testing standardization
Juarez, MJ; (...); Morais, S
Article. 10.1016/j.aca.2021.338656. 2021
Tubulo-interstitial inflammation increases the risk of graft loss after the recurrence of IgA nephropathy
Rodrigo E; (...); Hernández D
Article. 10.1093/ckj/sfad259. 2024
